Home Awareness CHMP Grants Favorable Opinion: Bristol Myers Melanoma

CHMP Grants Favorable Opinion: Bristol Myers Melanoma

Bristol Myers Squibb announces that the European Medicines Agency’s CHMP has recommended approval of Opdivo as an adjuvant therapy for patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

This positive opinion is based on safety and efficacy results from the Phase 3 CheckMate -76K trial, in which, with a minimum follow-up of 7.8 months, Opdivo reduced the risk of recurrence or death by 58% compared to placebo.

These results were presented at the 2022 annual meeting of the Society for Melanoma Research (SMR). The European Commission, which has the power to approve medicines in the European Union, will now review the CHMP recommendation.

This article is originally published on boursorama.com

Related Articles

AwarenessMedia Statements

A year of war in Ukraine and sanctions has deeply disrupted the...


Gaza Receives 20 Humanitarian Aid Trucks Today

In order to guarantee the total freedom of our editorial staff, Mediapart...


Youssef Amrani’s Journey: Brussels to Washington

From Brussels, the European capital, where he served as the Kingdom’s ambassador...


Defense: the European Union organizes its first military exercise in Spain

“A new page in the defense of the EU”, according to the...